The demo realized both its Key endpoints, with semaglutide 2.four mg demonstrating statistically substantial and top-quality enhancements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH when compared with placebo.oneSeveral habits and lifestyle de